231 related articles for article (PubMed ID: 9416775)
21. Conditioning to injection procedures and repeated testing increase SCH 23390-induced catalepsy in mice.
Chinen CC; Frussa-Filho R
Neuropsychopharmacology; 1999 Nov; 21(5):670-8. PubMed ID: 10516963
[TBL] [Abstract][Full Text] [Related]
22. Experimental catalepsy is both enhanced and disrupted by apomorphine.
Klemm WR
Psychopharmacology (Berl); 1985; 87(1):12-5. PubMed ID: 3933030
[TBL] [Abstract][Full Text] [Related]
23. Enhancement of Haloperidol-Induced Catalepsy by GPR143, an L-Dopa Receptor, in Striatal Cholinergic Interneurons.
Arai M; Suzuki E; Kitamura S; Otaki M; Kanai K; Yamasaki M; Watanabe M; Kambe Y; Murata K; Takada Y; Arisawa T; Kobayashi K; Tajika R; Miyazaki T; Yamaguchi M; Lazarus M; Hayashi Y; Itohara S; de Kerchove d'Exaerde A; Nawa H; Kim R; Bito H; Momiyama T; Masukawa D; Goshima Y
J Neurosci; 2024 Mar; 44(11):. PubMed ID: 38286627
[TBL] [Abstract][Full Text] [Related]
24. Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition.
Singh A; Naidu PS; Kulkarni SK
Pharmacology; 2003 Jun; 68(2):81-8. PubMed ID: 12711835
[TBL] [Abstract][Full Text] [Related]
25. Dopaminergic drugs influence the intensity of catalepsy induced by microinjections of carbachol into the reticular formation.
Elazar Z; Ganchrow D; Paz M; Rabinowitz R; Paz Z; Korczyn AD
Neurosci Lett; 1990 Nov; 119(2):245-8. PubMed ID: 1980731
[TBL] [Abstract][Full Text] [Related]
26. Adenosine A2 receptors modulate haloperidol-induced catalepsy in rats.
Mandhane SN; Chopde CT; Ghosh AK
Eur J Pharmacol; 1997 Jun; 328(2-3):135-41. PubMed ID: 9218695
[TBL] [Abstract][Full Text] [Related]
27. Adenosinergic modulation of 3alpha-hydroxy-5alpha-pregnan-20-one induced catalepsy in mice.
Mandhane SN; Khisti RT; Chopde CT
Psychopharmacology (Berl); 1999 Jun; 144(4):398-404. PubMed ID: 10435413
[TBL] [Abstract][Full Text] [Related]
28. Effects of buspirone on dopamine dependent behaviours in rats.
Dhavalshankh AG; Jadhav SA; Gaikwad RV; Gaonkar RK; Thorat VM; Balsara JJ
Indian J Physiol Pharmacol; 2007; 51(4):375-86. PubMed ID: 18476392
[TBL] [Abstract][Full Text] [Related]
29. D2 dopamine antisense RNA expression vector, unlike haloperidol, produces long-term inhibition of D2 dopamine-mediated behaviors without causing Up-regulation of D2 dopamine receptors.
Davidkova G; Zhou LW; Morabito M; Zhang SP; Weiss B
J Pharmacol Exp Ther; 1998 Jun; 285(3):1187-96. PubMed ID: 9618422
[TBL] [Abstract][Full Text] [Related]
30. Influence of dopamine energic pharmacology drugs on secretion of the adrenocorticotropic hormone from the hypophysis.
Milkov V; Pironcheva G; Miteva K; Russev G; Zlatarev S
Microbios; 2000; 102(403):155-8. PubMed ID: 10955829
[TBL] [Abstract][Full Text] [Related]
31. 3-O-methyldopa attenuates the effects of Madopar on the haloperidol-induced cataleptic behavior and the locomotor activity in the mouse.
Himori N; Tanaka Y; Kurasawa M; Mishima K; Akaike N
Pharmacology; 1994 Apr; 48(4):226-33. PubMed ID: 8177909
[TBL] [Abstract][Full Text] [Related]
32. Effect of cabergoline, a long-acting dopamine D2 agonist, on reserpine-treated rodents.
Miyagi M; Arai N; Taya F; Itoh F; Komatsu Y; Kojima M; Isaji M
Biol Pharm Bull; 1996 Nov; 19(11):1499-502. PubMed ID: 8951172
[TBL] [Abstract][Full Text] [Related]
33. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
Dekundy A; Pietraszek M; Schaefer D; Cenci MA; Danysz W
Brain Res Bull; 2006 Apr; 69(3):318-26. PubMed ID: 16564428
[TBL] [Abstract][Full Text] [Related]
34. Synergistic effects between D-1 and D-2 dopamine antagonists on catalepsy in rats.
Wanibuchi F; Usuda S
Psychopharmacology (Berl); 1990; 102(3):339-42. PubMed ID: 1979179
[TBL] [Abstract][Full Text] [Related]
35. CB1 cannabinoid receptor-mediated anandamide signaling mechanisms of the inferior colliculus modulate the haloperidol-induced catalepsy.
Medeiros P; de Freitas RL; Silva MO; Coimbra NC; Melo-Thomas L
Neuroscience; 2016 Nov; 337():17-26. PubMed ID: 27595886
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of bradykinesia induction by SM-9018, a novel 5-HT2 and D2 receptor antagonist, using the mouse pole test.
Ohno Y; Ishida K; Ikeda K; Ishibashi T; Okada K; Nakamura M
Pharmacol Biochem Behav; 1994 Sep; 49(1):19-23. PubMed ID: 7816873
[TBL] [Abstract][Full Text] [Related]
37. Antagonism of bromocriptine-induced cage climbing behaviour in mice by the selective D-2 dopamine receptor antagonists, metoclopramide and molindone.
Balsara JJ; Nandal NV; Gada VP; Bapat TR; Chandorkar AG
Indian J Physiol Pharmacol; 1986; 30(1):85-90. PubMed ID: 2950056
[TBL] [Abstract][Full Text] [Related]
38. FK506 as effective adjunct to L-dopa in reserpine-induced catalepsy in rats.
Singh A; Naidu PS; Kulkarni SK
Indian J Exp Biol; 2003 Nov; 41(11):1264-8. PubMed ID: 15332494
[TBL] [Abstract][Full Text] [Related]
39. Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol.
Yanahashi S; Hashimoto K; Hattori K; Yuasa S; Iyo M
Brain Res; 2004 Jun; 1011(1):84-93. PubMed ID: 15140647
[TBL] [Abstract][Full Text] [Related]
40. Interaction of antidepressants with antiparkinsonian agents in rats.
Zebrowska-Lupina I; Porowska A; Pietrasiewicz T
Pol J Pharmacol Pharm; 1985; 37(6):865-74. PubMed ID: 3832020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
